T1	Participants 54 104	patients with advanced non-small-cell lung cancer:
T2	Participants 107 198	quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
T3	Participants 284 321	metastatic non-small-cell lung cancer
T4	Participants 805 813	Patients
T5	Participants 1269 1301	37 pts (88%) in the DCT/CDDP arm
T6	Participants 1306 1339	39 pts (87%) in the VNR/CDDP one.
T7	Participants 2762 2806	pts with advanced non-small-cell lung cancer
